393 related articles for article (PubMed ID: 15319086)
1. Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines.
Stanberry LR
Herpes; 2004 Aug; 11 Suppl 3():161A-169A. PubMed ID: 15319086
[TBL] [Abstract][Full Text] [Related]
2. [Herpes simplex virus vaccine studies: from past to present].
Us D
Mikrobiyol Bul; 2006 Oct; 40(4):413-33. PubMed ID: 17205702
[TBL] [Abstract][Full Text] [Related]
3. Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs.
Bourne N; Bravo FJ; Francotte M; Bernstein DI; Myers MG; Slaoui M; Stanberry LR
J Infect Dis; 2003 Feb; 187(4):542-9. PubMed ID: 12599070
[TBL] [Abstract][Full Text] [Related]
4. Vaccines for herpes simplex virus infections.
Koelle DM
Curr Opin Investig Drugs; 2006 Feb; 7(2):136-41. PubMed ID: 16499283
[TBL] [Abstract][Full Text] [Related]
5. Vaccination strategies to prevent genital herpes and neonatal herpes simplex virus (HSV) disease.
Jones CA; Cunningham AL
Herpes; 2004 Apr; 11(1):12-7. PubMed ID: 15115632
[TBL] [Abstract][Full Text] [Related]
6. Comparison of different forms of herpes simplex replication-defective mutant viruses as vaccines in a mouse model of HSV-2 genital infection.
Da Costa XJ; Morrison LA; Knipe DM
Virology; 2001 Sep; 288(2):256-63. PubMed ID: 11601897
[TBL] [Abstract][Full Text] [Related]
7. Limited antibody-dependent cellular cytotoxicity antibody response induced by a herpes simplex virus type 2 subunit vaccine.
Kohl S; Charlebois ED; Sigouroudinia M; Goldbeck C; Hartog K; Sekulovich RE; Langenberg AG; Burke RL
J Infect Dis; 2000 Jan; 181(1):335-9. PubMed ID: 10608784
[TBL] [Abstract][Full Text] [Related]
8. Glycoprotein-D-adjuvant vaccine to prevent genital herpes.
Stanberry LR; Spruance SL; Cunningham AL; Bernstein DI; Mindel A; Sacks S; Tyring S; Aoki FY; Slaoui M; Denis M; Vandepapeliere P; Dubin G;
N Engl J Med; 2002 Nov; 347(21):1652-61. PubMed ID: 12444179
[TBL] [Abstract][Full Text] [Related]
9. Development of prophylactic vaccines for genital and neonatal herpes.
Jones CA; Cunningham AL
Expert Rev Vaccines; 2003 Aug; 2(4):541-9. PubMed ID: 14711338
[TBL] [Abstract][Full Text] [Related]
10. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
J Virol; 2017 May; 91(9):. PubMed ID: 28228587
[TBL] [Abstract][Full Text] [Related]
11. Comparison of intramuscular and footpad subcutaneous immunization with DNA vaccine encoding HSV-gD2 in mice.
Jazayeri M; Soleimanjahi H; Fotouhi F; Pakravan N
Comp Immunol Microbiol Infect Dis; 2009 Sep; 32(5):453-61. PubMed ID: 18571235
[TBL] [Abstract][Full Text] [Related]
12. Impact of immunization with glycoprotein D2/AS04 on herpes simplex virus type 2 shedding into the genital tract in guinea pigs that become infected.
Bourne N; Milligan GN; Stanberry LR; Stegall R; Pyles RB
J Infect Dis; 2005 Dec; 192(12):2117-23. PubMed ID: 16288376
[TBL] [Abstract][Full Text] [Related]
13. Ocular herpes simplex: changing epidemiology, emerging disease patterns, and the potential of vaccine prevention and therapy.
Pepose JS; Keadle TL; Morrison LA
Am J Ophthalmol; 2006 Mar; 141(3):547-557. PubMed ID: 16490506
[TBL] [Abstract][Full Text] [Related]
14. An update on short-course episodic and prevention therapies for herpes genitalis.
Corey L; Bodsworth N; Mindel A; Patel R; Schacker T; Stanberry L
Herpes; 2007 Jun; 14 Suppl 1():5A-11A. PubMed ID: 17877886
[TBL] [Abstract][Full Text] [Related]
15. Predicting the potential individual- and population-level effects of imperfect herpes simplex virus type 2 vaccines.
Schwartz EJ; Blower S
J Infect Dis; 2005 May; 191(10):1734-46. PubMed ID: 15838802
[TBL] [Abstract][Full Text] [Related]
16. A heat shock protein based polyvalent vaccine targeting HSV-2: CD4(+) and CD8(+) cellular immunity and protective efficacy.
Mo A; Musselli C; Chen H; Pappas J; Leclair K; Liu A; Chicz RM; Truneh A; Monks S; Levey DL; Srivastava PK
Vaccine; 2011 Nov; 29(47):8530-41. PubMed ID: 21767588
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of protective humoral immune responses against Herpes simplex virus-2 in DNA-immunized guinea-pigs using protein boosting.
Fotouhi F; Soleimanjahi H; Roostaee MH; Behzadian F
FEMS Immunol Med Microbiol; 2008 Oct; 54(1):18-26. PubMed ID: 18647350
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of glycoprotein D-adjuvant genital herpes vaccine.
Bernstein DI; Aoki FY; Tyring SK; Stanberry LR; St-Pierre C; Shafran SD; Leroux-Roels G; Van Herck K; Bollaerts A; Dubin G;
Clin Infect Dis; 2005 May; 40(9):1271-81. PubMed ID: 15825029
[TBL] [Abstract][Full Text] [Related]
19. Pediatrics and herpes simplex virus vaccines.
Rupp R; Rosenthal SL; Stanberry LR
Semin Pediatr Infect Dis; 2005 Jan; 16(1):31-7. PubMed ID: 15685147
[TBL] [Abstract][Full Text] [Related]
20. Rectal immunization generates protective immunity in the female genital tract against herpes simplex virus type 2 infection: relative importance of myeloid differentiation factor 88.
Tengvall S; O'Hagan D; Harandi AM
Antiviral Res; 2008 Jun; 78(3):202-14. PubMed ID: 18276020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
